The week in pharma: action, reaction and insight – week to May 24, 2024

26 May 2024

By Barbara Obstoj-Cardwell. Editor

UK pharma major AstraZeneca’s chief executive Sir Pascal Soriot outlined ambitious plans to increase revenue by nearly 75% to $80 billion by 2030. On the research front, US healthcare giant Johnson & Johnson released positive new data on its Tremfya in the treatment of ulcerative colitis (UC), and US biotech Tango Therapeutics announced that it is discontinuing development of its investigational cancer drug TNG348 due to toxicity. Also of note, the US Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation for Cartesian Therapeutics’ myasthenia gravis candidate Descartes-8.

AstraZeneca CEO’s bold ambitions

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK